Efficacy News and Research

RSS
Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients

Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients

Scientists use PGS method to analyse chromosomal status of eggs

Scientists use PGS method to analyse chromosomal status of eggs

Wake Forest Professor awarded $2.8M NHLBI grant to study ways to make transfusions using older blood safer

Wake Forest Professor awarded $2.8M NHLBI grant to study ways to make transfusions using older blood safer

Quick-Med Technologies announces application for EPA registration of Stay Fresh technology

Quick-Med Technologies announces application for EPA registration of Stay Fresh technology

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

Final results of VIAject vs. RHI Phase 3 study in type 2 diabetes patients presented at 70th ADA

Final results of VIAject vs. RHI Phase 3 study in type 2 diabetes patients presented at 70th ADA

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

EVISTA improves bone quality as measured by HRpQCT: IIT

EVISTA improves bone quality as measured by HRpQCT: IIT

Medtronic initiates enrollment in ASPIRE study of MiniMed Paradigm x54 Low Glucose Suspend integrated system

Medtronic initiates enrollment in ASPIRE study of MiniMed Paradigm x54 Low Glucose Suspend integrated system

Report: Health information technology could result in harm to patients without proper monitoring

Report: Health information technology could result in harm to patients without proper monitoring

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Antioxidant therapy may prevent long-lasting cognitive impairment in cerebral malaria: Research

Antioxidant therapy may prevent long-lasting cognitive impairment in cerebral malaria: Research

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Japan's MHLW grants full marketing authorization to REVLIMID

Japan's MHLW grants full marketing authorization to REVLIMID

Research provides hope and encouragement to people living with lupus

Research provides hope and encouragement to people living with lupus

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.